Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

New anti-human pai-1 antibody

A PAI-1, antibody technology, applied in the direction of antibodies, antibody medical components, recombinant DNA technology, etc.

Active Publication Date: 2016-10-12
ASTELLAS PHARMA INC
View PDF8 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, PAI-1, which forms a complex with tPA or uPA, binds to tPA or uPA, respectively, so this PAI-1 cannot perform new binding with other PAs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New anti-human pai-1 antibody
  • New anti-human pai-1 antibody
  • New anti-human pai-1 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] (Example 1: Study on immune antigen and preparation of hybridoma producing anti-human PAI-1 antibody)

[0185]In order to obtain highly selective antibodies against active human PAI-1, optimal human PAI-1 peptide antigens were studied. As a result of studying the length and amino acid sequence of the peptide, it was found that Multiple Antigen Peptide 8 (Multiple Antigen Peptide 8, MAP8) (J. Biol. Chem., 1988, Vol. 263, No. 4, p. 1719-1725) peptide immunization can obtain antibodies that neutralize active human PAI-1 in plasma. The results of further original research on the protein linked to the antigen, the immunization method, etc. showed that the peptide with the keyhole limpet hemocyanin (Keyhole Limpet Hemocyanin, KLH) protein linked to the C-terminus of the peptide antigen and the recombinant active human When PAI-1 (Molecular Innovation, PAI-A) is mixed and immunized at the same time, the active form that strongly neutralizes the active form of human PAI-1 in p...

Embodiment 2

[0187] (Example 2: ELISA detection)

[0188] To measure the antigen-specific binding activity of antibodies, ELISA assays were used. Here, in order to evaluate the selectivity to active human PAI-1, a plate prepared by immobilizing vitronectin and adding active human PAI-1 was used, and latent human PAI-1 was added instead of active human PAI. -1 and made the board to test.

[0189] Dilute vitronectin (BD Biosciences, 354238) with phosphate-buffered saline (PBS) to 1000 ng / mL, add 100 μL per well to a Nunc Maxisorp transparent 96 plate (Nunc company), and place the plate at 4°C Overnight, thereby immobilizing vitronectin. The vitronectin solid phase was removed by reverse centrifugation, and recombinant active human PAI-1 (Molecular Innovation, PAI-A) or recombinant latent human PAI diluted to a concentration of 1000 ng / mL with PBS was added at 100 μL per well. -1 (Molecular Innovation, PAI-L), left still at 4°C for 1 hour. The solution was removed by reverse centrifugatio...

Embodiment 3

[0192] (Example 3: Production of fully human antibody)

[0193] The above antibodies are antibodies in which the variable regions are derived from humans and the constant regions are derived from mice. Therefore, the present inventors constructed an expression vector containing both heavy chain and light chain genes using a GS vector (Lonza Corporation), which is a vector for expression in mammalian cells, and produced a fully human antibody. Specifically, for HOT-1 identified in Example 2, RNA was extracted from the hybridoma, and cDNA was prepared using a cDNA amplification kit (SMARTer RACE cDNA amplification kit; Clontech). Next, the variable regions of the heavy and light chains are extended and amplified using the polymerase chain reaction (PCR). The gene encoding the signal sequence (Nigel Whittle et al., Protein Engineering, 1987, Vol.1, No.6, p.499-505) was connected to the 5' side of the heavy chain variable region gene of HOT-1, and then at the 3' The constant reg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

[Problem] To provide an anti-human PAI-1 antibody for prevention and treatment of pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by active human PAI-1. [Solution] The inventors studied anti-PAI-1 antibodies, and provided an anti-human PAI-1 antibody that contains: a heavy-chain variable region comprising the amino acid sequence from amino acid 1 to 118 in SEQ ID No. 2; and a light-chain variable region comprising the amino acid sequence from amino acid 1 to 108 in SEQ ID No. 4.

Description

technical field [0001] The present invention relates to novel anti-human PAI-1 antibodies. Background technique [0002] Plasminogen activator inhibitor-1 (plasminogen activator inhibitor-1; PAI-1) is one of the serine protease inhibitors produced by vascular endothelium and the like. PAI-1 binds to plasminogen activator (PA), which is a serine protease, and inactivates the enzymatic activity of PA (Mol. Cell. Endocrinol., 1990, Vol. 68, p. 1-19). In PAI-1, there are active PAI-1, latent PAI-1, and PAI-1 that forms a complex with PA, and only active PAI-1 has the property of PAI-1 that inhibits PA (Blood, 1987, Vol.70, p.1090-1098). There are tissue plasminogen activator (tissue plasminogen activator; tPA) and urokinase-type plasminogen activator (urokinase-type plasminogen activator; uPA; also known as urokinase) in PA, both of which make plasminogen Activated to be converted into plasmin, thereby catalyzing a reaction for dissolving fibrin produced in blood coagulation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/09A61K39/395A61P7/02A61P11/00A61P41/00C07K16/38C12N1/15C12N1/19C12N1/21C12N5/10C12P21/08
CPCA61P7/02A61P11/00A61P41/00C07K16/38C07K2317/21C07K2317/24C07K2317/33C07K2317/76C12N2510/02A61K39/395A61K2039/505C07K2317/56C12N15/63A61K39/39533A61K2039/507C07K2317/565C07K2317/94
Inventor 田中祐嗣吉野正康
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com